Download PDF
Thromb Haemost 1987; 57(02): 158-164
DOI: 10.1055/s-0038-1651086
Original Article
Schattauer GmbH Stuttgart

Hemorrhagic Thrombocytopathy with Platelet Thromboxane A2 Receptor Abnormality: Defective Signal Transduction with Normal Binding Activity

Fumitaka Ushikubi
1   The First Division, Department of Medicine, Kyoto University Faculty of Medicine, Kyoto, Japan
,
Minoru Okuma
1   The First Division, Department of Medicine, Kyoto University Faculty of Medicine, Kyoto, Japan
,
Kenji Kanaji
1   The First Division, Department of Medicine, Kyoto University Faculty of Medicine, Kyoto, Japan
,
Tateo Sugiyama
1   The First Division, Department of Medicine, Kyoto University Faculty of Medicine, Kyoto, Japan
,
Toshiya Ogorochi
2   The Department of Medical Chemistry, Kyoto University Faculty of Medicine, Kyoto, Japan
,
Shuh Narumiya
2   The Department of Medical Chemistry, Kyoto University Faculty of Medicine, Kyoto, Japan
,
Haruto Uchino
1   The First Division, Department of Medicine, Kyoto University Faculty of Medicine, Kyoto, Japan
› Author Affiliations
Further Information

Publication History

Received 08 October 1986

Accepted after revision 16 December 1986

Publication Date:
28 June 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Subnormal platelet responses to thromboxane A2 (TXA2) were found in a patient with polycythemia vera, and the mechanism of this dysfunction was analyzed. The patient’s platelets showed defective aggregation and release reaction to arachidonic acid, enzymatically generated TXA2 and synthetic TXA2 mimetics (STA2, U-46619). In contrast, they showed normal responses to thrombin. When the platelet TXA2 receptor was examined with both a 125I-labelled derivative of a TXA2 receptor antagonist ([125I]-PTA-OH) and a 3H-labelled TXA2 agonist ([3H]U-46619), the equilibrium dissociation rate constants (Kd) and the maximal concentrations of binding sites (Bmax) of the patient’s platelets to both ligands were within normal ranges, suggesting that the binding capacity of their TXA2 receptor was normal. STA2 failed to induce normal elevation in the. cytoplasmic free calcium ion concentration, phosphatidic acid formation and 40 kD protein phosphorylation in the patient’s platelets, whereas these responses to thrombin were within normal ranges. 12-O-Tetradecanoyl-phorbol-13-acetate (TPA) also evoked normal response in the 40 kD protein phosphorylation in the patient’s platelets. These results suggested that the patient’s platelets had TXA2 receptor abnormalities which were characterized by defective transduction of the binding signal to postreceptor reactions after normal TXA2 binding.

Keywords

Platelet thromboxane A2 receptor - Defective signal transduction - Platelet dysfunction - Polycythemia vera
 

  • References

  • 1 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998
    CrossrefPubMedGoogle Scholar
  • 2 Wu KK, Le Breton GC, Tai H H, Chen YC. Abnormal platelet response to thromboxane A2 . J Clin Invest 1981; 67: 1801-1804
    CrossrefPubMedGoogle Scholar
  • 3 Lages B, Malmsten C, Weiss HJ, Samuelsson B. Impaired platelet response to thromboxane A2and defective calcium mobilization in a patient with a bleeding disorder. Blood 1981; 57: 545-552
    PubMedGoogle Scholar
  • 4 Samama M, Lecrubier C, Conrad J, Hotchen M, Breton-Gorius J, Vargaftig B, Chignard M, Lagarde M, Dechavanne M. Constitutional thrombocytopathy with subnormal response to thromboxane A2 . Br J Haematol 1981; 48: 293-303
    CrossrefPubMedGoogle Scholar
  • 5 Hattori A, Takahashi H, Takahashi M, Shibata A, Okuma M. A new familial defect of platelet release mechanism (The intracellular Ca++transport defect?). Acta Haematol Jpn 1981; 44: 969-972
    PubMedGoogle Scholar
  • 6 Okuma M, Takayama H, Uchino H. Subnormal platelet response to thromboxane A2in a patient with chronic myeloid leukaemia. Br J Haematol 1982; 51: 469-477
    CrossrefPubMedGoogle Scholar
  • 7 Machin SJ, Keenan JP, McVerry BA. Defective platelet aggregation to the calcium ionophore A23187 in a patient with a lifelong bleeding disorder. J Clin Pathol 1983; 36: 1140-1144
    CrossrefPubMedGoogle Scholar
  • 8 Hardisty RM, Machin SJ, Nokes T JC, Rink TJ, Smith SW. A new congenital defect of platelet secretion: impaired responsiveness of the platelets to cytoplasmic free calcium. Br J Haematol 1983; 53: 543-557
    CrossrefPubMedGoogle Scholar
  • 9 Rink TJ, Smith SW, Tsien RY. Cytoplasmic free Ca2+in human platelets: Ca2+threshholds and Ca-independent activation for shapechange and secretion. FEBS Lett 1982; 148: 21-26
    CrossrefPubMedGoogle Scholar
  • 10 Johnson PC, Ware JA, Cliveden PB, Smith B, Dvorak AA, Salzman EW. Measurement of ionized calcium in blood platelets with the photoprotein aequorin: Comparison with quin 2. J Biol Chem 1985; 260: 2069-2076
    PubMedGoogle Scholar
  • 11 Berridge MJ, Irvine RF. Inositol triphosphate, a novel second messenger in cellular signal transduction. Nature 1984; 312: 315-321
    CrossrefPubMedGoogle Scholar
  • 12 Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 1984; 308: 693-698
    CrossrefPubMedGoogle Scholar
  • 13 Kawahara Y, Takai Y, Minakuchi R, Sano K, Nishizuka Y. Phospholipid turnover as a possible transmembrane signal for protein phosphorylation during human platelet activation by thrombin. Biochem Biophys Res Commun 1980; 97: 309-317
    CrossrefPubMedGoogle Scholar
  • 14 Bundy GL. Synthesis of prostaglandin endoperoxide analogs. Tetrahedron Lett 1975; 1957-1960
    PubMedGoogle Scholar
  • 15 Le Breton GC, Venton DL, Enke SE, Halushka PV. 13-Azaprostanoic acid: A specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Proc Natl Acad Sci USA 1979; 76: 4097-4101
    CrossrefPubMedGoogle Scholar
  • 16 Nicolaou KC, Magolda RL, Smith JB, Aharony D, Smith EE, Lefer AM. Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. Proc Natl Acad Sci USA 1979; 76: 2566-2570
    CrossrefPubMedGoogle Scholar
  • 17 Jones RL, Peesapati V, Wilson NH. Antagonism of the thromboxane-sensitive contractile systems of the rabbit aorta, dog saphenous vein and guinea-pig trachea. Br J Pharmacol 1982; 76: 423-438
    CrossrefPubMedGoogle Scholar
  • 18 Katsura M, Miyamoto T, Hamanaka N, Kondo K, Terada T, Ohgaki Y, Kawasaki A, Tsuboshima M. In vitro and in vivo effects of new powerful thromboxane antagonists (3-alkylamino pinane derivatives). In Advances in Prostaglandin Thromboxane and Leukotriene Research. vol. 11 Samuelsson B, Paoletti R, Ramwell P. (eds). pp 351-357 Raven Press; New York: 1983
    Google Scholar
  • 19 Hung SC, Ghali NI, Venton DL, Le Breton GC. Specific binding of the thromboxane A2antagonist 13-azaprostanoic acid to human platelet membranes. Biochim Biophys Acta 1983; 728: 171-178
    CrossrefPubMedGoogle Scholar
  • 20 Armstrong RA, Jones RL, Wilson NH. Ligand binding to thromboxane receptors on human platelets: correlation with biological activity. Br J Pharmacol 1983; 79: 953-964
    CrossrefPubMedGoogle Scholar
  • 21 Halushka PV, MacDermot J, Knapp DR, Eller T, Saussy Jr D L, Mais D, Blair IA, Dollery CT. A novel approach for the study of thromboxane A2and prostaglandin H2receptors using an 125I-labelled ligand. Biochem Pharmacol 1985; 34: 1165-1170
    CrossrefPubMedGoogle Scholar
  • 22 Burch RM, Mais DE, Saussy Jr D L, Halushka PV. Solubilization of a thromboxane A2/prostaglandin H2antagonist binding site from human platelets. Proc Natl Acad Sci USA 1985; 82: 7434-7438
    CrossrefPubMedGoogle Scholar
  • 23 Narumiya S, Okuma M, Ushikubi F. Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species. Br J Pharmacol 1986; 88: 323-331
    CrossrefPubMedGoogle Scholar
  • 24 Kawahara Y, Yamanishi J, Furuta Y, Kaibuchi K, Takai Y, Fukuzaki H. Elevation of cytoplasmic free calcium concentration by stable thromboxane A2analogue in human platelets. Biochem Biophys Res Commun 1983; 117: 663-669
    CrossrefPubMedGoogle Scholar
  • 25 Pollock WK, Armstrong RA, Brydon LJ, Jones RL, MacIntyre DE. Thromboxane-induced phosphatidate formation in human platelets. Biochem J 1984; 219: 833-842
    CrossrefPubMedGoogle Scholar
  • 26 Mielke CH, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34: 204-215
    PubMedGoogle Scholar
  • 27 Okuma M, Uchino H. Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Blood 1979; 54: 1258-1271
    PubMedGoogle Scholar
  • 28 Takayama H, Okuma M, Uchino H. A simple method for estimation of lipoxygenase and cyclooxygenase pathways in human platelets - the use of thiobarbituric acid reaction. Thromb Haemostas 1980; 44: 111-114
    PubMedGoogle Scholar
  • 29 Newhouse P, Chonk C. The variability of platelet aggregation. In The Platelet Function. Triplett PA. (ed). pp 43-107 American Society of Clinical Pathologists; Chicago: 1978
    Google Scholar
  • 30 Okuma M. Platelet function and arachidonate metabolism in patients with myeloproliferative disorders. Acta Haematol Jpn 1980; 43: 1139-1144
    PubMedGoogle Scholar
  • 31 Hallam TJ, Sanchez A, Rink TJ. Stimulus-response coupling in human platelets: Changes evoked by platelet-activating factor in cytoplasmic free calcium monitored with the fluorescent calcium indicator quin 2. Biochem J 1984; 218: 819-827
    CrossrefPubMedGoogle Scholar
  • 32 Tsien RY, Pozzan T, Rink TJ. Calcium homeostasis in intact lymphocytes: cytoplasmic free calcium monitored with a new, intracellularly trapped fluorescence indicator. J Cell Biol 1982; 94: 325-334
    CrossrefPubMedGoogle Scholar
  • 33 Lloyd JV, Nishizawa EE, Haldar J, Mustard JF. Changes in 32P-labelling of platelet phospholipids in response to ADP. Br J Haematol 1972; 23: 571-585
    CrossrefPubMedGoogle Scholar
  • 34 Yavin E, Zutra A. Separation and analysis of 32P-labeled phospholipids by a simple and rapid thin-layer chromatographic procedure and its application to cultured neuroblastoma cells. Anal Biochem 1977; 80: 430-437
    CrossrefPubMedGoogle Scholar
  • 35 Feinstein MB, Egan JJ, Opas EE. Reversal of thrombin-induced myosin light chain phosphorylation and the assembly of cytoskeletal structures in platelets by the adenylate cyclase stimulant prostaglandin D2and forskolin. J Biol Chem 1983; 258: 1260-1267
    PubMedGoogle Scholar
  • 36 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 37 Siess W, Siegel FL, Lapetina EG. Arachidonic acid stimulates the formation of 1,2-diacylglycerol and phosphatidic acid in human platelets. J Biol Chem 1983; 258: 11236-11242
    PubMedGoogle Scholar
  • 38 Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 1-12
    PubMedGoogle Scholar
  • 39 Ullich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TT, Schlessinger J, Downward J, Mayers E LV, Whittle N, Waterfield MD, Seeburg PH. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309: 418-425
    CrossrefPubMedGoogle Scholar
  • 40 Ullich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull T J, Gray A, Coussens L, Liao YC, Tsubokawa M, Mason A, Seeburg PH, Grunfeld C, Rosen OM, Ramachandran J. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985; 313: 756-761
    CrossrefPubMedGoogle Scholar
  • 41 Russel DW, Schneider WJ, Yamamoto T, Luskey KL, Brown MM, Goldstein JL. Domain map of the LDL receptor: sequence homology with the epidermal growth factor precursor. Cell 1984; 37: 577-585
    CrossrefPubMedGoogle Scholar